Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
IBCSG 55-17 “Touch” Phase II open-label, multicenter, randomized trial of neo-adjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer
Dec 4, 2018CDK4/6-Inhibitoren bringen enorme Verbesserungen bei der Behandlung von Patienten mit fortgeschrittenen, HR+ (Hormonrezeptor positiv)/HER2- (human epidermal growth factor receptor 2 negativ) BC (Brustkrebserkrankungen). Palbociclib und andere CDK4/6-...
Clinical Studies - Dec 4, 2018 - Dec 31, 2021
Automatically Closed
Project leader: Weder Patrik
TLD-1, a novel Liposomal Doxorubicin, in Patients with Advanced Solid Tumors; a multicenter open-label single-arm phase I trial.
Oct 26, 2018In dieser Studie wird zum ersten Mal die Sicherheit und Wirksamkeit eines neuen Medikaments (Talidox) bei Menschen untersucht. Bei dem neuen Medikament handelt es sich um einen bekannten Wirkstoff, das Chemotherapeutikum Doxorubicin, welches in einer...
Clinical Studies - Oct 26, 2018 - Dec 31, 2026
Ongoing
Project leader: Hess Dagmar
Members: Harder Anja, Quinter Janine
Trial SAKK 19/17: First line durvalumab in patients with PD-L1 positve, advanced NSCLC with performance status 2 unsuitable for combination chemotherapy. A multicenter, single-arm phase II trial
Oct 23, 2018Lung cancer is the leading cause of cancer deaths. An estimated 30 to 40% of patients diagnosed with NSCLC have a poor PS defined as a score of 2 or higher on the ECOG scale. PS 2 patients are often underrepresented in clinical trials despite represe...
Clinical Studies - Oct 23, 2018 - Nov 23, 2021
Automatically Closed
Project leader: Früh Martin
SAKK 57/16. NAPAGE NAb-PAclitaxel and GEmcita-bine in advanced soft tissue sarcoma. A multicenter open-label single arm phase Ib/IIa trial
Oct 2, 2018Multizentrische Phase Ib/IIa Studie für Patientinnen und Patienten mit metastasiertem Weichteilsarkom, welche bereits eine oder zwei palliative Chemothera-pien erhalten haben. Zunächst erfolgt eine Dosisfin-dung mit Nab-Paclitaxel and Gemcitabine un...
Clinical Studies - Oct 2, 2018 - Oct 9, 2021
Automatically Closed
Project leader: Rothermundt Christian
Identifying and targeting the “Achilles’ heel” in proteasome inhibitor-resistant multiple myeloma
Oct 1, 2018The proposal aims at understanding the biology of proteasome inhibitor (PI)-refractory multiple myeloma (MM), in particular the specific vulnerabilities of PI-refractory MM, or so called “Achilles’ heel”, towards development of novel treatment option...
Fundamental Research - Oct 1, 2018 - Dec 31, 2021
Automatically Closed
Project leader: Driessen Christoph
Members: Besse Andrej, Kraus Marianne, Besse Lenka, Mendez Lopez Max
Randomisierte klinische Studie zum Vergleich der Vollständigkeit der adjuvanten Chemotherapie nach früher vs. später Stomarückverlagerung bei Patienten mit Rektumkarzinom nach tiefer anteriorer Resektion
Sep 24, 2018Ziel der CoCStom-Studie ist es, den optimalen Zeitpunkt der Rückverlagerung eines künstlichen Darmausgangs (Stoma) zu ermitteln, der im Rahmen der chirurgischen Entfernung des Mastdarms beim lokal fortgeschrittenen Enddarmkrebs (Rektumkarzinom) vorüb...
Clinical Studies - Sep 24, 2018 - Nov 30, 2020
Completed
Project leader: Marti Lukas, Kienle P, Hofheinz R
Members: Beutner Ulrich, Gueller Ulrich, Brunner Walter, Bischofberger Stephan
International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing’s Sarcoma Family of Tumours
Aug 30, 2018The objective of the induction/consolidation chemotherapy randomisation (R1) is to compare the VIDE strategy (VIDE induction and VAI/VAC/BuMel consolidation) with the VDC/IE strategy (compressed VDC/IE induction and IE/VC/Bu-Mel consolidation). The e...
Clinical Studies - Aug 30, 2018 - Aug 14, 2014
Automatically Closed
Project leader: Appenzeller Christina
Alternate day dosing of Pomalidomide in patients with re-fractory Multiple
Aug 17, 2018Multiple myeloma (MM) accounts for 1% of all cancers and ∼10% of all hematological malignancies. Despite recent advances in myeloma treatment, including the introduction of proteasome inhibitors, immunomodulatory drugs (IMiDs) and stem cell transplan...
Clinical Studies - Aug 17, 2018 - Apr 23, 2023
Automatically Closed
Project leader: Silzle Tobias
Tailored AXILLary Surgery with or without axillary lymph node dissection followed by radotherapy in patients with clinically node-positive breast cancer (TAXIS)
Jul 30, 2018The removal of all lymph nodes in the armpit through con-ventional axillary dissection has been standard care for all patients with breast cancer for almost a century. In the nineties, the sentinel lymph node (SLN) procedure, which involves the selec...
Clinical Studies - Jul 30, 2018 - Dec 12, 2030
Ongoing
Project leader: Bekes Inga
Members: Sennhauser Andrina, Frehner Jan
An Observatinal Study of Blinatumomab Safety and Effec-tiveness, Utillisation, and Treatment Practice
Jul 11, 2018Study Background and Rationale As a new treatment for acute lymphoblastic leukaemia (ALL), it is important tounderstand the safety and effective-ness of Blincyto (blinatumomab) as it isadministered in routine clinical practice. This study, developed...
Clinical Studies - Jul 11, 2018 - Feb 22, 2022
Automatically Closed
Project leader: Silzle Tobias
Randomisierte, offene, multizentrische Phase-2/3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Ro-garatinib (BAY 1163877) im Vergleich zu Chemotherapie bei Patienten mit FGFR-positivem, lokal fortgeschritte-nem oder metastatischem Urothelkarzinom, die vorher eine platinhaltige Chemotherapie erhalten haben
May 30, 2018Rogaratinib ist ein oraler pan-FGFR inhibitor. Eine FGFR-Überexpression (vorallem FGFR3 isoform) kann in bis zu 40% aller Patienten mit metastasiertem Urothelkarzinom nachgewiesen werden und stellt einen oncogenic driver da. Die Studie untersucht Rog...
Clinical Studies - May 30, 2018 - Dec 31, 2030
Ongoing
Project leader: Schmid Sabine
Patient-needs-based multi-professional delivery of Palliative Interventions by oncologists’ and oncology nurses: a randomized Phase II trial
May 22, 2018Background: Evidence is emerging that early specialist palliative care (SPC) is effective in several defined clinical settings and that it consists of a variety of definable palliative interventions (PCI). PCI encompass pharmacological, procedural, e...
Clinical Studies - May 22, 2018 - May 22, 2018
Automatically Closed
Members: Schmidt Mary Helen, Domeisen Benedetti Franzisca, Attoun-Knobel Suzanne, Behnke Nadine
Multicentre Oberservational Study of MDS Patients in Switzerland- Swiss MDS Registry
May 17, 2018Die Myelodysplastischen Syndrome (MDS) umfassen eine heterogene Gruppe hämatologischer Stammzellerkran-kungen, welche durch Reifungsstörungen des Knochen-markes (Dysplasien) mit Verminderung der Blutzellen (Zy-topenien) charakterisiert sind. Das Spek...
Clinical Studies - May 17, 2018 - Aug 14, 2030
Ongoing
Project leader: Silzle Tobias
Members: Steiner Marianne, Frehner Jan
TRIANGLE: autologous Transplantation after a Rituxi-mab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European mcl net-work trial
Feb 20, 2018According to current European guidelines (Dreyling, Ann Oncol 2014), the standard of care in younger patients with mantle cell lymphoma (MCL) is a dose-intensified approach with a cytarabine containing immunochemotherapy induction followed by autolog...
Clinical Studies - Feb 20, 2018 - Jan 31, 2028
Ongoing
Project leader: Hitz Felicitas
Protocol SAKK 07/17: Nivolumab in combination with I-pilimumab in patients with metastatic renal cell carcinoma: A multicentre single-arm phase lI trial
Jan 4, 2018Superior overall survival of PD-1 blockade with nivolumab compared to everolimus has been shown in the phase III Checkmate-025 trial in metastatic clear cell carcinoma of the kidney in second line after progression under first line therapy with a tyr...
Clinical Studies - Jan 4, 2018 - Oct 31, 2021
Automatically Closed
Project leader: Rothermundt Christian
Effect of induction chemotherapy on lung function measured by spiroergometry and 6-Minute walking test in patients affected by non-small cell lung cancer (NSCLC)
Jan 1, 2018Lung cancer is one of the most common cancers in the world and the leading cause of cancer-related mortality. At diagnosis, approximately 40% of patients are already at an advanced stage, and a third have locally advanced disease (stage III). Stage I...
Fundamental Research - Jan 1, 2018 - Dec 31, 2020
Automatically Closed
Members: Baty Florent, Brutsche Martin, Kern Lukas, Maeder Micha, Früh Martin
A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected ad-vanced solid tumors and non-Hodgkin lymphoma
Oct 5, 2017This is a multi-center, open label, phase 2 study to evaluate efficacy of the NIR178 and PDR001 combination in NSCLC, other solid tumors, and diffuse large B-cell lymphoma (DLBCL). The study has three parts: part 1: Multi-arm Bayesian adaptive signal...
Clinical Studies - Oct 5, 2017 - Feb 20, 2024
Automatically Closed
Project leader: Jörger Markus
SAKK 17/16: Lurbinectedin Monotherapy in Pa-tients with Progressive Malignant Pleural Mesothelioma. A Multicenter, Single-arm Phase II Trial
Sep 29, 2017Malignant mesothelioma arises from the mesothelial cells of the pleural, peritoneal or pericardial lining and is often associated with asbestos exposition (Robinson, 2005). There is no cure for most malignant mesotheliomas and the scope of all three...
Clinical Studies - Sep 29, 2017 - Sep 29, 2021
Automatically Closed
Project leader: Früh Martin
Randomisierte, doppelblinde, placebokontrollierte Pha-se III-Studie zu Rovalpituzumab Tesirin als Erhaltungs-therapie nach einer Erstlinienchemotherapie auf Platin-basis bei Studienteilnehmern mit ausgebreitetem (exten-sive-stage) kleinzelligem Bronchialkarzinom (MERU)
Sep 22, 2017Industrie gesponserte Studie zur Evaluation der Wirksamkeit (hinsichtlich OS und PFS) von Rovalpituzumab Tesirin beim SCLC, eingesetzt als Erhaltungstherapie nach Erstli-nientherapie. Rovalpituzumab Tesirin ist ein Antikörper-Wirkstoff Konju-gat, wob...
Clinical Studies - Sep 22, 2017 - Mar 31, 2019
Automatically Closed
Project leader: Früh Martin
The MENAC Trial - A randomised, open-label trial of a multimodal intervention (multimodal = exercise, nutrition and anti-inflammatory medication) versus standard care in cancer patients with cachexia
Aug 24, 2017Cachexia is a common detrimental consequence of cancer limiting therapy, quality of life and survival. There is no standard treatment available and its complex multifactorial pathophysiology requires multimodal treatment. Based on promising phase II...
Clinical Studies - Aug 24, 2017 - May 31, 2020
Automatically Closed
Project leader: Strasser Florian, Domeisen Benedetti Franzisca
Members: Attoun-Knobel Suzanne, Behnke Nadine